`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_______________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________
`
`STEADYMED LTD.
`Petitioner
`
`v.
`
`UNITED THERAPEUTICS CORPORATION
`Patent Owner
`
`
`
`U.S. Patent No. 8,497,393
`Issue Date: Jul. 30, 2013
`Title: PROCESS TO PREPARE TREPROSTINIL, THE ACTIVE INGREDIENT IN
`REMODULIN®
`_______________
`
`Case IPR2016-00006
`_______________
`
`
`
`PATENT OWNER’S MOTION TO EXCLUDE
`
`
`
`
`4850-9319-7872.1
`
`
`
`IPR2016-00006
`Patent 8,497,393
`
`
`Patent Owner Docket No. 080618-1601
`
`
`
`INTRODUCTION
`
`I.
`Under 37 C.F.R. § 42.64(c) and the Scheduling Order (Paper 13), United
`
`Therapeutics Corporation (“Patent Owner”) moves to exclude Petitioner’s Exhibit
`
`1022 and the objected-to portions of Exhibits 1009, 1022 and 2059 on the
`
`following grounds:
`
`Exhibit
`
`Description
`
`Reason to Exclude
`
`Ex. 1009
`
`Declaration of Jeffrey D.
`
`Expert not qualified to make these
`
`Winkler, Ph.D. (¶¶3, 31, 46, 48,
`
`conclusory statements
`
`54, 57, 63, 71, and 72)
`
`Ex. 1017
`
`A website printout entitled
`
`Hearsay and not authenticated
`
`“Getting Started in HPLC,’
`
`Section 4D: Precision and
`
`Accuracy”
`
`Ex. 1022
`
`Dr. Robin D. Rogers
`
`Exceeds scope of PO Response
`
`Declaration
`
`and does not rely on facts and data
`
`Ex. 2059
`
`Certain portions of Deposition
`
`Likely to create confusion and
`
`in the record
`
`Transcript of Dr. Robert M.
`
`mislead
`
`Williams, Ph.D
`
`4850-9319-7872.1
`
`2
`
`
`
`IPR2016-00006
`Patent 8,497,393
`
`
`
`
`Patent Owner Docket No. 080618-1601
`
`
`
`Petitioner relied on these exhibits as pointed out below in its Petition (Paper
`
`No. 1) and Petitioner’s Reply (Paper No. 52). Patent Owner also moves to exclude
`
`the portions of Petitioner’s Petition and Reply, which rely on these exhibits.
`
`II.
`
`PATENT OWNER TIMELY OBJECTED
`
`Patent Owner timely objected, on April 22, 2016, to Exhibits 1009 and 1017,
`
`which were submitted with the Petition, which was instituted on April 12, 2016.
`
`See Paper 19. Likewise, Patent Owner timely objected, on October 3, 2016, to
`
`Exhibits 1022 and 2059, which were submitted with the Reply, which was filed on
`
`September 27, 2016. See Paper 55. Petitioner did not supplement or authenticate
`
`any of its evidence in response to these specific objections.
`
`A. Ex. 1009
`
`Specifically, Patent Owner objected to Ex. 1009 in Paper No. 19 for the
`
`following reasons:
`
`Exhibit 1009 is described as “Declaration of Jeffrey D. Winkler, Ph.D.” Patent
`
`Owner objects to Exhibit 1009, under FRE 701, because the opinion testimony
`
`contained in this exhibit reaches legal conclusions for which the declarant has not
`
`established that he is capable of providing, for example, paragraphs 3, 31, 46, 48,
`
`4850-9319-7872.1
`
`3
`
`
`
`IPR2016-00006
`Patent 8,497,393
`
`
`Patent Owner Docket No. 080618-1601
`
`
`
`54, 57, 63, 71, and 72 each recite an unsupported legal conclusion and, thus,
`
`should not be considered by the Board is this proceeding.
`
`B. Ex. 1017
`
`Patent Owner objected to Ex. 1017 in Paper No. 19 for the following reasons:
`
`Exhibit 1017 is described as “‘Getting Started in HPLC,’ Section 4D: Precision
`
`and Accuracy, available at http://www.lcresources.com/resources/getstart/
`
`4d01.htm (accessed Sept. 29, 2015).” Patent Owner objects to Exhibit 1017 under
`
`FRE 901 as not being properly authenticated. Petitioner relies on the exhibit to
`
`prove the truth of the matter asserted therein, but the exhibit fails to meet the
`
`requirements of any hearsay exception or exemption under FRE 803-807.
`
`C. Ex. 1022
`
`Patent Owner objected to Ex. 1022 in Paper No. 55 for the following reasons:
`
`Exhibit 1022 is described as “Dr. Robin D. Rogers Declaration.”
`
`(a) Patent Owner objects to Exhibit 1022 under 37 CFR 42.23 because the
`
`opinion testimony contained in this exhibit contains opinions, including
`
`paragraphs 44-48, that are not responsive to the Patent Owner Response and,
`
`thus, should not be considered by the PTAB in this proceeding. See 37
`
`C.F.R. § 41.41(b);
`
`4850-9319-7872.1
`
`4
`
`
`
`IPR2016-00006
`Patent 8,497,393
`
`
`Patent Owner Docket No. 080618-1601
`
`
`
`(b) Patent Owner objects to Exhibit 1022 under FRE 702-703 as including
`
`opinions, including paragraphs 84-86, that rely on facts and data that are not
`
`in the record as to how a melting point was calculated;
`
`(c) Patent Owner objects to Exhibit 1022 under FRE 702-703 as including
`
`opinions, including paragraph 87, that rely on facts and data that are not in
`
`the record to conclude that a melting point range is narrow.
`
`D. Ex. 2059
`
`Patent Owner objected to Ex. 2059 in Paper No. 55 for the following reasons:
`
`Patent Owner objects to the Reply at pages 2, 3, 4, 7, 8, and 24 for citing
`
`portions of Ex. 2059 (Williams deposition transcript at 112-113 and 217-219)
`
`under FRE 402-403 as being likely to cause confusion pursuant to the objection
`
`made at the deposition at p. 112 of the transcript that the questions
`
`mischaracterized earlier testimony and documents shown to the witness.
`
`Patent Owner objects to the Reply at page 15 for citing portions of Ex. 2059
`
`(Williams deposition transcript at 180) under FRE 402-403 as being likely to cause
`
`confusion pursuant to the objection made at the deposition at p. 181 of the
`
`transcript that the earlier questions misrepresented the document shown to the
`
`witness.
`
`
`
`4850-9319-7872.1
`
`5
`
`
`
`IPR2016-00006
`Patent 8,497,393
`
`
`III. ARGUMENT
`
`Patent Owner Docket No. 080618-1601
`
`
`
`A. The Conclusory Statements of Dr. Winkler (Ex. 1009) Should be
`Excluded
`
`Under FRE 702, a witness may be qualified to testify as an expert if “the
`
`expert’s scientific, technical, or other specialized knowledge will help the trier of
`
`fact to understand the evidence or to determine a fact in issue.” In paragraphs 3,
`
`31 46, 48, 54, 57, 63, 71, and 72 of his declaration (Ex. 1009), Dr. Winkler gives
`
`opinions for which he lacks the requisite expertise.
`
`While Dr. Winkler may be qualified in organic chemistry, Dr. Winkler offers
`
`several opinions that are purely legal conclusions or otherwise unsupported
`
`conclusory statements about subjects that he is not qualified to make. For
`
`example, in each of the paragraphs cited above, Dr. Winker concludes that a prior
`
`art reference either “anticipates,” “inherently” discloses or renders “obvious”
`
`claim limitations. Anticipation, inherency and obviousness are legal concepts that
`
`are beyond Dr. Winker’s expertise. Rather, Dr. Winker’s declaration should be
`
`limited to his opinions that are within the field of organic chemistry. Accordingly,
`
`paragraphs 3, 31, 46, 48, 54, 57, 63, 71, and 72 of Exhibit 1017 should be
`
`excluded. See The Medicines Co. v. Mylan Inc., No. 11-CV-1285, 2014 WL
`
`1758135, at *6 (N.D. Ill. May 2, 2014) (“expert testimony that contains a legal
`
`conclusion that determines the outcome of a case is inadmissible.”).
`
`4850-9319-7872.1
`
`6
`
`
`
`IPR2016-00006
`Patent 8,497,393
`
`
`Patent Owner Docket No. 080618-1601
`
`
`
`These conclusory statements of Dr. Winkler are relied upon in the Petition at
`
`pp. 21, 24, and 25 and in the Petitioner’s Reply at p. 11, which accordingly, should
`
`also be excluded.
`
`B.
`
`Exhibit 1017 Should be Excluded as Inadmissible Hearsay and
`Not Properly Authenticated Evidence
`
`Exhibit 1017 should be excluded because it contains hearsay under FRE 802.
`
`The asserted copyright date and asserted revision date on page 3 of the exhibit are
`
`hearsay (as are the purported web address and the date in the footer of the
`
`document). See Hilgraeve, Inc. v. Symantec Corp., 271 F. Supp. 2d 964, 974 (E.D.
`
`Mich. 2003) (copyright “dates imprinted on . . . documents are hearsay when
`
`offered to prove the truth of the matter asserted”). In his declaration (Ex. 1009),
`
`Dr. Winkler relies on Exhibit 1017 for the proposition that “the literature on
`
`HPLC's precision indicates that the ‘RSD’ or ‘relative standard deviation’ for a
`
`typical instrument is about 1%.” Exhibit 1009 at ¶ 70. It appears that Dr.
`
`Winkler’s statement at ¶ 70 is referencing the text of Ex. 1017 which reads: “[f]or
`
`most purposes, HPLC methods are expected to have CV values on the order of
`
`1%” (see Winkler Deposition Transcript, Ex. 2051 at pp. 97-98). This statement in
`
`Ex. 1017 (relied upon by Dr. Winkler at ¶ 70 of his Declaration) is simply hearsay
`
`for which no exception applies and should be excluded. See FRE 802.
`
`4850-9319-7872.1
`
`7
`
`
`
`IPR2016-00006
`Patent 8,497,393
`
`
`Patent Owner Docket No. 080618-1601
`
`
`
`Exhibit 1017 should also be excluded because it has not been authenticated
`
`pursuant to FRE 901, and it is not a self-authenticating document pursuant to FRE
`
`902. Petitioner offers it as a print-out from a web site (Petition, Paper 1 at ii) but
`
`has made no attempt to authenticate the exhibit following Patent Owner’s
`
`objection. Petitioner provided no testimony from any witness about when, where,
`
`or how this document was obtained. Petitioner could have provided supplemental
`
`evidence directed to authentication, but Petitioner provided no testimony from any
`
`witness that Ex. 1017 is what Petitioner purports it to be. Printouts from web sites
`
`are not self-authenticating. See Veeam Software Corp. v. Symantec Corp.,
`
`IPR2013-00142, Paper 11 at 9 (P.T.A.B. Aug. 7, 2013) (“under the Federal Rules
`
`of Evidence, authentication of [website printouts] is required”). Accordingly,
`
`Exhibit 1017 has not been properly authenticated and should be excluded.
`
`The Winkler Declaration (Ex. 1009) relies upon Ex. 1017 in paragraph 70. In
`
`addition, the Petition relies upon these portions of the Winkler Declaration and Ex.
`
`1017 at pp. 21, 29, 44, 45, and 56, and the Petitioner’s Reply relies upon them at
`
`pp. 12, 13, and 15.
`
`C. Certain Portions of Dr. Rogers’ Declaration (Ex. 1022) Should be
`Excluded
`
`First, paragraphs 44-48 of Dr. Roger’s declaration (Ex. 1022) do not respond to
`
`the Patent Owner Response and should be excluded under 37 C.F.R. § 41.41(b). In
`
`4850-9319-7872.1
`
`8
`
`
`
`IPR2016-00006
`Patent 8,497,393
`
`
`Patent Owner Docket No. 080618-1601
`
`
`
`paragraphs 44-48 of his declaration, Dr. Rogers provides opinions about Form A’s
`
`melting point range and also thermogravimetric analysis. However, these opinions
`
`do not rebut any portion of the Patent Owner Response. Accordingly, such
`
`opinions are new opinions, which are not proper for an expert declaration
`
`submitted with a Petitioner Reply brief, and should be excluded under 37 C.F.R. §
`
`41.41(b).
`
`Second, paragraphs 84-86 rely on facts and data that are not in the record and
`
`are improper under FRE 702-703. Paragraphs 84-87 offer opinions as to how a
`
`melting point is calculated by an unspecified piece of software and also the relative
`
`breadth of a melting point range without any reference being cited against which to
`
`judge the breadth of the range. These paragraphs are not supported by citation to
`
`any reference and merely conclusory statements made by Dr. Rogers.
`
`Accordingly, such opinions should be excluded.
`
`These paragraphs of Dr. Roger’s Declaration are relied upon in Petitioner’s
`
`Reply at p. 15, which accordingly, should also be excluded.
`
`D. The Portions of Dr. Williams’ Testimony That Were
`Mischaracterized Should be Excluded
`
`Petitioner’s Reply to Patent Owner’s Response includes a number of
`
`statements and references that misrepresent certain testimony from the deposition
`
`transcript of Dr. Williams (Ex. 2059). In particular, in these pages of the Reply,
`
`4850-9319-7872.1
`
`9
`
`
`
`IPR2016-00006
`Patent 8,497,393
`
`
`Patent Owner Docket No. 080618-1601
`
`
`
`Petitioner mischaracterizes portions of Dr. Williams’ testimony despite the
`
`objections of Patent Owner’s counsel (Ms. Hasper), who objected that Petitioner’s
`
`counsel (Mr. Pollack) had mischaracterized earlier testimony and various exhibits
`
`(Ex. 2059 at 112:22-113:20, 180:9-25, 217:11-219:20), which renders Dr.
`
`Williams testimony confusing, misleading, and more prejudicial than probative,
`
`and, therefore, inadmissible under FRE 403.
`
`First, Patent Owner objects to the Petitioner’s Reply at pages 2, 3, 4, 7, 8, and
`
`24 for citing portions of Ex. 2059 (Williams deposition transcript at pp. 112-113
`
`and 217-219) under FRE 402-403 as being likely to cause confusion pursuant to
`
`the objection made at the deposition at p. 112 of the Williams deposition transcript
`
`that the questions in those sections mischaracterized his earlier testimony and
`
`documents shown to the witness.
`
`Second, Patent Owner objects to the Petitioner’s Reply at page 15 for citing
`
`portions of Ex. 2059 (Williams deposition transcript at p. 180) under FRE 402-403
`
`as being likely to cause confusion pursuant to the objection made at the deposition
`
`at p. 181 of the transcript that the earlier questions misrepresented the document
`
`shown to the witness.
`
`4850-9319-7872.1
`
`10
`
`
`
`IPR2016-00006
`Patent 8,497,393
`
`
`Patent Owner Docket No. 080618-1601
`
`
`
`These mischaracterized portions of Dr. Williams’ testimony are relied upon in
`
`Petitioner’s Reply at pp. 2, 3, 4, 7, 8, 15, and 24, which accordingly, should also be
`
`excluded.
`
`IV. CONCLUSION
`
`For at least the reasons provided above, Patent Owner urges the Board to grant
`
`this motion and exclude exhibits Exhibit 1017, the objected-to portions of Exhibits
`
`1009, 1022 and 2059, as well as the arguments of Petitioner that rely on these
`
`exhibits in the Petition and in Petitioner’s Reply as set forth above.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`/Stephen B. Maebius/
`Stephen B. Maebius
`Registration No. 35,264
`Counsel for Patent Owner
`
`
`Date: Nov. 1, 2016
`
`
`
`
`
`
`
`4850-9319-7872.1
`
`11
`
`
`
`IPR2016-00006
`Patent 8,497,393
`
`
`Attorney Docket No. 080618-1601
`
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that a copy of the foregoing Patent Owner’s Motion to
`
`Exclude was served on counsel of record on Nov. 1, 2016, by filing this document through the
`
`PTAB E2E System as well as delivering a copy via email to the counsel of record for the
`
`Petitioner at the following address: Steadymed-IPR@dlapiper.com.
`
`/Stephen B. Maebius/
`Stephen B. Maebius
`Foley & Lardner LLP
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Date: Nov. 1, 2016
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`4850-9319-7872.1